Are you Dr. Mills?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Gordon Mills, MD is an obstetrician/gynecologist in Houston, Texas. He is currently licensed to practice medicine in Texas. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of AlbertaClass of 1977
Certifications & Licensure
TX State Medical License 1996 - 2018
Publications & Presentations
PubMed
- 110 citationsThe role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.Gordon B. Mills, Yiling Lu, Xianjun Fang, Hongwei Wang, Astrid Eder
Seminars in Oncology. 2001-10-01 - 2101 citationsThe Molecular Taxonomy of Primary Prostate CancerAdam Abeshouse, Jaeil Ahn, Rehan Akbani, Adrian Ally, Samirkumar B. Amin
Cell. 2015-11-05 - 4823 citationsThe cancer genome atlas pan-cancer analysis projectJohn N. Weinstein, Eric A. Collisson, Gordon B. Mills, Kenna R. Mills Shaw, Brad Ozenberger
Nature Genetics. 2013-10-01
Press Mentions
Pangea Biomed Begins Pilot Collaboration with the OHSU Knight Cancer Institute to Improve Cancer Therapy PrecisionOctober 24th, 2024- How OHSU's 'SMMART' Cancer Trial Helped Guide One Patient to Unconventional TreatmentsJune 17th, 2022
- The Topic of CancerJune 16th, 2022
- Join now to see all
Grant Support
- Biological Annotation Of TCGA DataNational Cancer Institute2012
- The Role Of Aberrant Splicing Of Evl1 In Ovarian Cancer PathophysiologyNational Cancer Institute2008–2012
- Role Of RAB25 And Its Effectors In Breast Cancer BioengenericsNational Cancer Institute2010–2011
- P4 - Pers. Therapy For High-Grade Ovarian Cancer: Targeting Pi3kness &BrcaneNational Cancer Institute2010–2011
- Modeling Response To P13K Targeted TherapiesNational Cancer Institute2010–2011
- Modeling Response To P13K Target TherapiesNational Cancer Institute2010–2011
- Predictors Of Resistance Dual Vegfr/Egfr Targeted Therapy Of Head And Neck CancerNational Cancer Institute2009–2011
- Integrative Pipeline For Analysis &Translational Application Of TCGA Data (GDAC)National Cancer Institute2009–2011
- Targeting The PI3K Pathway In Ovarian CancerNational Cancer Institute2008–2009
- P-3: Predictors Of Resistnace Todual Vegfr/Egfr Targeted Therapy Of H&N CancerNational Cancer Institute2008
- MMAC1/PTEN Tumor Suppressor And Breast CancerNational Cancer Institute1999–2003
- PI-3 Kinase Pathway In Ovarian CancerNational Cancer Institute2001–2002
- LPA In Initiation And Progression In Ovarian CancerNational Cancer Institute2001–2002
- Phosphatidylinositol Signaling In Ovarian Tumorigenesis, Prognosis &TherapyNational Cancer Institute1999–2002
- CD Signaling Through Emt/Itk Tyrosine KinaseNational Cancer Institute1997–2001
- Ovarian Cancer Activating Factor In Ovarian Cancer Initiation And ProgressionNational Cancer Institute1996–2000
- Putative Tumor Suppressor Ptp1c In Breast CancerNational Cancer Institute1996–1998
